Meropenem - Antibiogram Data

Outpatients (Urinary Isolates)
% of Isolates Susceptible

These organisms may produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility

May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility.

May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility.

Overall extended spectrum beta-lactamase (ESBL) activity was seen in a weighted average of 6.2% of samples of E.coli, K.pneumoniae and P.mirabilis

Overall extended spectrum beta-lactamase (ESBL) activity was seen in a weighted average of 6.2% of samples of E.coli, K.pneumoniae and P.mirabilis

May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility

May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility.

May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility

Note

  • January 1, 2019 - December 31, 2019

  • R: Intrinsically resistant